Literature DB >> 21943707

Mitochondria as a sequestration site for incomplete TCRβ peptides: the TCRβ transmembrane domain is a sufficient mitochondrial targeting signal.

Nir Shani1, Vera Shinder, Dov Zipori.   

Abstract

The existence of incomplete T cell receptor (TCR) mRNA forms, including germline transcripts and products of unfruitful TCR rearrangements, has long been known. However, it is unclear whether these molecules are functional. We have previously shown that T cells also contain truncated TCRβ peptides that lack the N-terminal part and contain C-terminus sequences. These partial forms of TCRβ, target the mitochondrion and induce apoptosis, exhibiting a novel mode of TCR mediated cell death. Here we aimed at analyzing the minimal TCR sequences that direct the peptide to the mitochondrion. It is shown that truncated TCRβ, targets mitochondria and induces mitochondrial perinuclear clustering, in both monkey COS-7 and human 293 cells. These phenomena are mediated by the C-terminus of the molecule. Whereas the positively charged amino acids flanking the transmembrane domain (TMD) of TCRβ are beneficial for this process, they are not essential. Indeed, the isolated TMD of TCRβ serves as a sufficient mitochondrial targeting sequence. These results indicate that any given partial form of TCRβ, that contains the TMD, is bound to be sequestered by the mitochondrion. This may assure that incomplete TCR forms would not interfere with correct TCR complex formation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21943707     DOI: 10.1016/j.molimm.2011.08.018

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  1 in total

1.  Eph A10-modified pH-sensitive liposomes loaded with novel triphenylphosphine-docetaxel conjugate possess hierarchical targetability and sufficient antitumor effect both in vitro and in vivo.

Authors:  Jiulong Zhang; Chunrong Yang; Shuang Pan; Menghao Shi; Jie Li; Haiyang Hu; Mingxi Qiao; Dawei Chen; Xiuli Zhao
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.